North America Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others), By Type, By Country and Growth Forecast, 2021 - 2027
Description
North America Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others), By Type, By Country and Growth Forecast, 2021 - 2027
The North America Immune Checkpoint Inhibitors Market would witness market growth of 15.6% CAGR during the forecast period (2021-2027).
Immune checkpoints are a necessary aspect of the immune system's operations. Their objective is to keep the immune system from overreacting and destroying viable cells in the body. When proteins over the surface of immune cells, which are also called T cells, recognize and attach to partner proteins on other cells, such as tumor cells, immunological checkpoints get activated. These proteins are known as immune checkpoint proteins. When the checkpoint and companion proteins bind, the T cells receive an "off" signal. This may prevent the tumor from being destroyed by the immune system.
T cells are used by the immune system to fight cancer. These highly specialized cells are exceedingly powerful and can cause harm to healthy cells. Immune checkpoints, which can be positive or negative, regulate T cell activity. Positive immunological checkpoints encourage T cells to keep working, whereas negative immune checkpoints prevent T cells from doing so.
Lung cancer is the second most common cancer in the US, according to the American Cancer Society Inc's estimates for 2020, with 135,720 deaths in both men and women. According to statistics, small cell lung cancer (SCLC) accounts for about 13% of all lung cancers in the United States, while non-small cell lung cancer (NSCLC) accounts for 84 percent. This trend is expected to continue in the future, resulting in increased demand for these products.
Moreover, The CTLA-4-blocking ipilimumab for melanoma was licensed by the US Food and Drug Administration (FDA) in 2011 as the first checkpoint inhibitor immunotherapy for cancer treatment. Since then, the FDA has approved seven checkpoint inhibitors for the treatment of more than a dozen cancers.
The US market dominated the North America Immune Checkpoint Inhibitors Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $30,476.5 million by 2027. The Canada market is anticipated to grow at a CAGR of 18.2% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 17.2% during (2021 - 2027).
Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segments covered in the Report:
By Application
The North America Immune Checkpoint Inhibitors Market would witness market growth of 15.6% CAGR during the forecast period (2021-2027).
Immune checkpoints are a necessary aspect of the immune system's operations. Their objective is to keep the immune system from overreacting and destroying viable cells in the body. When proteins over the surface of immune cells, which are also called T cells, recognize and attach to partner proteins on other cells, such as tumor cells, immunological checkpoints get activated. These proteins are known as immune checkpoint proteins. When the checkpoint and companion proteins bind, the T cells receive an "off" signal. This may prevent the tumor from being destroyed by the immune system.
T cells are used by the immune system to fight cancer. These highly specialized cells are exceedingly powerful and can cause harm to healthy cells. Immune checkpoints, which can be positive or negative, regulate T cell activity. Positive immunological checkpoints encourage T cells to keep working, whereas negative immune checkpoints prevent T cells from doing so.
Lung cancer is the second most common cancer in the US, according to the American Cancer Society Inc's estimates for 2020, with 135,720 deaths in both men and women. According to statistics, small cell lung cancer (SCLC) accounts for about 13% of all lung cancers in the United States, while non-small cell lung cancer (NSCLC) accounts for 84 percent. This trend is expected to continue in the future, resulting in increased demand for these products.
Moreover, The CTLA-4-blocking ipilimumab for melanoma was licensed by the US Food and Drug Administration (FDA) in 2011 as the first checkpoint inhibitor immunotherapy for cancer treatment. Since then, the FDA has approved seven checkpoint inhibitors for the treatment of more than a dozen cancers.
The US market dominated the North America Immune Checkpoint Inhibitors Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $30,476.5 million by 2027. The Canada market is anticipated to grow at a CAGR of 18.2% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 17.2% during (2021 - 2027).
Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segments covered in the Report:
By Application
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
- PD-1 Inhibitor
- PD-L1 Inhibitor
- CTLA-4 Inhibitor
- US
- Canada
- Mexico
- Rest of North America
- AstraZeneca PLC
- Beigene Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Merck Group (Merck Sharp & Dohme Corp.)
- Sanofi S.A.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
83 Pages
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Immune Checkpoint Inhibitors Market, by Application
- 1.4.2 North America Immune Checkpoint Inhibitors Market, by Type
- 1.4.3 North America Immune Checkpoint Inhibitors Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition and scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Acquisition and Mergers
- 3.2.3 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
- 3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
- Chapter 4. North America Immune Checkpoint Inhibitors Market by Application
- 4.1 North America Lung Cancer Market by Country
- 4.2 North America Bladder Cancer Market by Country
- 4.3 North America Melanoma Market by Country
- 4.4 North America Hodgkin lymphoma Market by Country
- 4.5 North America Other Application Market by Country
- Chapter 5. North America Immune Checkpoint Inhibitors Market by Type
- 5.1 North America PD-1 Inhibitor Market by Country
- 5.2 North America PD-L1 Inhibitor Market by Country
- 5.3 North America CTLA-4 Inhibitor Market by Country
- Chapter 6. North America Immune Checkpoint Inhibitors Market by Country
- 6.1 US Immune Checkpoint Inhibitors Market
- 6.1.1 US Immune Checkpoint Inhibitors Market by Application
- 6.1.2 US Immune Checkpoint Inhibitors Market by Type
- 6.2 Canada Immune Checkpoint Inhibitors Market
- 6.2.1 Canada Immune Checkpoint Inhibitors Market by Application
- 6.2.2 Canada Immune Checkpoint Inhibitors Market by Type
- 6.3 Mexico Immune Checkpoint Inhibitors Market
- 6.3.1 Mexico Immune Checkpoint Inhibitors Market by Application
- 6.3.2 Mexico Immune Checkpoint Inhibitors Market by Type
- 6.4 Rest of North America Immune Checkpoint Inhibitors Market
- 6.4.1 Rest of North America Immune Checkpoint Inhibitors Market by Application
- 6.4.2 Rest of North America Immune Checkpoint Inhibitors Market by Type
- Chapter 7. Company Profiles
- 7.1 AstraZeneca PLC
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Regional Analysis
- 7.1.4 Research & Development Expenses
- 7.1.5 Recent strategies and developments:
- 7.1.5.1 Partnerships, Collaborations, and Agreements:
- 7.1.5.2 Approvals and Trials:
- 7.2 Beigene Ltd.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Regional Analysis
- 7.2.4 Research & Development Expenses
- 7.2.5 Recent strategies and developments:
- 7.2.5.1 Partnerships, Collaborations, and Agreements:
- 7.3 Shanghai Junshi Biosciences Co., Ltd.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Research & Development Expenses
- 7.4 Bristol Myers Squibb Company
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional Analysis
- 7.4.4 Research & Development Expenses
- 7.4.5 Recent strategies and developments:
- 7.4.5.1 Partnerships, Collaborations, and Agreements:
- 7.4.5.2 Approvals and Trials:
- 7.5 GlaxoSmithKline PLC (GSK)
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Segmental and Regional Analysis
- 7.5.4 Research & Development Expense
- 7.6 Eli Lilly and Company
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expense
- 7.7 Merck Group (Merck Sharp & Dohme Corp.)
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Segmental and Regional Analysis
- 7.7.4 Research & Development Expense
- 7.7.5 Recent strategies and developments:
- 7.7.5.1 Partnerships, Collaborations, and Agreements:
- 7.8 Sanofi S.A.
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
- 7.8.5 Recent strategies and developments:
- 7.8.5.1 Partnerships, Collaborations, and Agreements:
- 7.8.5.2 Approvals and Trials:
- 7.8.5.3 Acquisition and Mergers:
- 7.9 Merck & Co., Inc.
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Segmental and Regional Analysis
- 7.9.4 Research & Development Expenses
- 7.9.5 Recent strategies and developments:
- 7.9.5.1 Partnerships, Collaborations, and Agreements:
- 7.9.5.2 Approvals and Trials:
- 7.10. F. Hoffmann-La Roche Ltd.
- 7.10.1 Company Overview
- 7.10.2 Financial Analysis
- 7.10.3 Segmental and Regional Analysis
- 7.10.4 Research & Development Expense
- 7.10.5 Recent strategies and developments:
- 7.10.5.1 Partnerships, Collaborations and Agreements:
- 7.10.5.2 Approvals and Trials:
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
